Clinical Trials
17 trialsNCT05264974 2026-05-27
Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization
University of Florida
Phase 1 Suspended
NCT06391099 2026-05-26
Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer
Ohio State University Comprehensive Cancer Center
Phase NA Suspended
NCT04866810 2026-04-27
The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)
National Institutes of Health Clinical Center (CC)
Phase NA Suspended
NCT04418167 2025-09-03
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
JS InnoPharm, LLC
Phase 1 Suspended
NCT03384836 2025-07-02
Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery
Roswell Park Cancer Institute
Phase 1/2 Suspended
NCT05669352 2025-04-04
A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases
University of Florida
Phase 1/2 Suspended
NCT04714983 2024-04-09
DNX-2440 for Resectable Colorectal Liver Metastasis
DNAtrix, Inc.
Phase 1 Suspended
NCT03932253 2024-03-27
MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 1 Suspended
NCT05756556 2024-02-01
T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma
ImmVira Pharma Co. Ltd
Phase 2 Suspended
NCT04427306 2023-09-15
Neoadjuvant T-VEC in High Risk Early Melanoma
University of California, Davis
Phase 2 Suspended
NCT03970382 2022-08-18
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
PACT Pharma, Inc.
Phase 1 Suspended
NCT01988831 2019-05-10
Efficacy of Propranolol Treatment to Prevent Melanoma Progression
University Hospital, Geneva
Phase 2 Suspended
NCT01841463 2014-09-04
Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
Piramal Enterprises Limited
Phase 1 Suspended
NCT00278122 2013-12-10
Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
University of Virginia
Phase 2 Suspended
NCT00160992 2005-09-12
Adoptive Cell Transfer Combined With Peptide Vaccination in Transiently Immunosuppressed Melanoma Patients
University of Lausanne Hospitals
Phase 1 Suspended
NCT00033956 2005-06-24
Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2
MetaPhore Pharmaceuticals
Phase 1/2 Suspended
NCT00042497 2005-06-24
Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma
Anosys
Phase 2 Suspended